Literature DB >> 11574612

Longitudinal variability of human immunodeficiency virus type 1 RNA viral load measurements by nucleic acid sequence-based amplification and NucliSens assays in a large multicenter study.

M J Nowicki1, L Benning, J W Bremer, W A Meyer, C Hanson, D Brambilla, S Silver, A Kovacs.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) RNA measurements were evaluated within an externally controlled multilaboratory program. Three external standards (1.5 x 10(3) to 1.5 x 10(6) copies/ml) were included in 814 assay runs by four laboratories. Results indicate that HIV-1 RNA levels can be measured with a precision equal to that of the pre-highly active antiretroviral therapy era (standard deviations, +/-0.16 to 0.25 log10 units).

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11574612      PMCID： PMC88428          DOI： 10.1128/JCM.39.10.3760-3763.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Relationship of incremental specimen volumes and enhanced detection of human immunodeficiency virus type 1 RNA with nucleic acid amplification technology.

Authors:  D J Witt; M Kemper; A Stead; C C Ginocchio; A M Caliendo
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis.

Authors:  M Clerici; A Sarin; R L Coffman; T A Wynn; S P Blatt; C W Hendrix; S F Wolf; G M Shearer; P A Henkart
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

3.  The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Authors:  P Gerondelis; R H Archer; C Palaniappan; R C Reichman; P J Fay; R A Bambara; L M Demeter
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days.

Authors:  S G Deeks; R L Coleman; R White; C Pachl; M Schambelan; D N Chernoff; M B Feinberg
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

5.  The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program.

Authors:  D Brambilla; P S Reichelderfer; J W Bremer; D E Shapiro; R C Hershow; D A Katzenstein; S M Hammer; B Jackson; A C Collier; R S Sperling; M G Fowler; R W Coombs
Journal:  AIDS       Date:  1999-11-12       Impact factor: 4.177

6.  Accuracy of plasma HIV RNA quantification: a multicentre study of variability.

Authors:  S J Skidmore; M Zuckerman; J V Parry
Journal:  J Med Virol       Date:  2000-08       Impact factor: 2.327

7.  Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.

Authors:  D Brambilla; S Leung; J Lew; J Todd; S Herman; M Cronin; D E Shapiro; J Bremer; C Hanson; G V Hillyer; G D McSherry; R S Sperling; R W Coombs; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

9.  Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H J Lin; L Pedneault; F B Hollinger
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728
View more
  8 in total

1.  Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women.

Authors:  Marek J Nowicki; Tomasz Laskus; Georgia Nikolopoulou; Marek Radkowski; Jeffrey Wilkinson; Wenbo B Du; Jorge Rakela; Andrea Kovacs
Journal:  J Infect Dis       Date:  2005-09-29       Impact factor: 5.226

2.  Oral and systemic health correlates of HIV-1 shedding in saliva.

Authors:  M Navazesh; R Mulligan; N Kono; S K S Kumar; M Nowicki; M Alves; W J Mack
Journal:  J Dent Res       Date:  2010-07-29       Impact factor: 6.116

3.  Systemic and mucosal differences in HIV burden, immune, and therapeutic responses.

Authors:  Sharon M Wahl; Maryann Redford; Shawna Christensen; Wendy Mack; Jon Cohn; Edward N Janoff; Jiri Mestecky; Hal B Jenson; Mahvash Navazesh; Mardge Cohen; Patricia Reichelderfer; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

4.  Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.

Authors:  Xiuhong Li; Haitao Chu; Joel E Gallant; Donald R Hoover; Wendy J Mack; Joan S Chmiel; Alvaro Muñoz
Journal:  J Epidemiol Community Health       Date:  2006-09       Impact factor: 3.710

5.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

6.  Quality assurance in the HIV/AIDS laboratory network of China.

Authors:  Yan Jiang; Maofeng Qiu; Guiyun Zhang; Wenge Xing; Yao Xiao; Pinliang Pan; Jun Yao; Chin-Yih Ou; Xueli Su
Journal:  Int J Epidemiol       Date:  2010-12       Impact factor: 7.196

7.  Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs.

Authors:  Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs
Journal:  J Infect Dis       Date:  2003-07-01       Impact factor: 5.226

8.  First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease.

Authors:  Juan C Ramírez; Rudy Parrado; Elena Sulleiro; Anabelle de la Barra; Marcelo Rodríguez; Sandro Villarroel; Lucía Irazu; Cristina Alonso-Vega; Fabiana Alves; María A Curto; Lineth García; Lourdes Ortiz; Faustino Torrico; Joaquim Gascón; Laurence Flevaud; Israel Molina; Isabela Ribeiro; Alejandro G Schijman
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.